Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Actuate Therapeutics Inc (ACTU)
USD1.72
-0.01 (-0.58%)
US NASDAQ Healthcare Biotechnology
Address
1751 River Run 76107
Fort Worth, TX, US
Fort Worth, TX, US
CEO
Daniel Schmitt
Website
actuatetherapeutics.com
IPO
2024-08-13
CIK 1652935 ISIN US0050831009
Description
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.72
-0.01 (-0.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
183.3K
Beta
0.68
Float Shares
8.34M
Free Float %
34.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.25% | -15.92% | +5.19% | -42.82% | -60.16% | -60.29% | -76.32% | -71.78% | -71.78% | -71.78% | -71.78% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.72
Low
21.00
+1,120.9%
Consensus
21.00
+1,120.9%
Median
21.00
+1,120.9%
High
21.00
+1,120.9%
DCF (Unlevered)
0.54
-68.6%
DCF (Levered)
0.61
-64.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
21.00
+1,120.9%
|
Quality scores
Altman Z-Score
-25.94
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+67.5% ★ Q1'26: +25.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +578.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.7% Q1'26: +20.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
6.24M
6.24M – 6.24M
|
33.39M
33.39M – 33.39M
+435.5% YoY
|
68.24M
68.24M – 68.24M
+104.4% YoY
|
100.93M
100.93M – 100.93M
+47.9% YoY
|
| EBITDA |
-25.16M
|
-22.50M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-27.30M
|
-22.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-27.29M
est: -61.67M (+55.8%)
|
-22.23M
est: -22.65M (+1.9%)
|
-14.93M
-16.42M – -13.43M
+34.1% YoY
|
-16.92M
-19.44M – -14.41M
-13.4% YoY
|
-19.92M
-19.92M – -19.92M
-17.7% YoY
|
-14.98M
-14.98M – -14.98M
+24.8% YoY
|
16.08M
16.08M – 16.08M
+207.4% YoY
|
| SGA |
6.48M
|
12.20M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.26
est: -3.16 (-3.2%)
|
-1.06
est: -1.08 (+1.6%)
|
-0.71
-0.78 – -0.64
+34.1% YoY
|
-0.81
-0.92 – -0.69
-13.4% YoY
|
-0.95
-0.95 – -0.95
-17.7% YoY
|
-0.71
-0.71 – -0.71
+24.8% YoY
|
0.77
0.77 – 0.77
+207.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-22 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
60
Total invested
37.97M
Insider transactions (90d)
1
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AARON GLENN LOUIS FLETCHER | 10.13M | 52.80% | 77.1K | 10.05M | 77.1K | 10.00 | IN | UNITED STATES | 2024-08-19 | ↗ |
| 2 | BIOS ADVISORS GP, LLC | 10.05M | 52.40% | — | 10.05M | — | 10.00 | OO | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 3 | BIOS CAPITAL MANAGEMENT, LP | 10.05M | 52.40% | — | 10.05M | — | 10.00 | PN | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 4 | LESLIE WAYNE KREIS, JR. | 8.73M | 45.50% | 69.4K | 8.66M | 69.4K | 10.00 | IN | UNITED STATES | 2024-08-19 | ↗ |
| 5 | CAVU ADVISORS, LLC | 8.66M | 45.20% | — | 8.66M | — | 10.00 | OO | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 6 | CAVU MANAGEMENT, LP | 8.66M | 45.20% | — | 8.66M | — | 10.00 | PN | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 7 | BIOS EQUITY PARTNERS III, LP | 5.96M | 31.20% | — | 5.96M | — | 10.00 | PN | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 8 | BIOS FUND III QP, LP | 2.51M | 13.10% | — | 2.51M | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 9 | BIOS ACTUATE CO-INVEST II, LP | 2.09M | 11.00% | — | 2.09M | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 10 | BIOS EQUITY PARTNERS II, LP | 1.75M | 9.10% | — | 1.75M | — | 10.00 | PN | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 11 | BIOS EQUITY COF, LP | 1.38M | 7.20% | — | 1.38M | — | 10.00 | PN | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 12 | BIOS CLINICAL OPPORTUNITY FUND, LP | 1.26M | 6.60% | — | 1.26M | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 13 | BIOS FUND II QP, LP | 1.01M | 5.30% | — | 1.01M | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 14 | BIOS EQUITY PARTNERS, LP | 950.1K | 5.00% | — | 950.1K | — | 10.00 | PN | TEXAS, UNITED STATES | 2024-08-19 | ↗ |
| 15 | BIOS ACTUATE CO-INVEST III, LP | 573.4K | 3.00% | — | 573.4K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 16 | BIOS FUND I, LP | 525.8K | 2.80% | — | 525.8K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 17 | BIOS FUND III NT, LP | 404.8K | 2.10% | — | 404.8K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 18 | BIOS FUND III, LP | 383.8K | 2.00% | — | 383.8K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 19 | BIOS FUND II, LP | 308.2K | 1.60% | — | 308.2K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 20 | BIOS FUND I QP, LP | 307.5K | 1.60% | — | 307.5K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 21 | BIOS ACTUATE CO-INVEST I, LP | 300.7K | 1.60% | — | 300.7K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 22 | BIOS FUND II NT, LP | 134.8K | 0.70% | — | 134.8K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 23 | BIOS 2024 CO-INVEST, LP | 125.0K | 0.70% | — | 125.0K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
| 24 | BP DIRECTORS, LP | 116.8K | 0.60% | — | 116.8K | — | 10.00 | PN | DELAWARE, UNITED STATES | 2024-08-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
60
+16 vs prev Q
New positions
22
Closed positions
6
Increased
41
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BIOS CAPITAL MANAGEMENT, LP | 10.05M +— (+0.0%) | 61.51M -5.7M (-8.5%) | 46.97% -4.181 pp | 74.44% -1.177 pp | USD7.94 -22.9% | 5 qtrs — |
| 2 | VOSS CAPITAL, LLC | 1.30M +403.7K (+45.0%) | 7.96M +2.0M (+32.7%) | 6.08% +1.514 pp | 0.38% +0.092 pp | USD6.51 -6.0% | 5 qtrs — |
| 3 | VANGUARD GROUP INC | 529.1K +213.1K (+67.4%) | 3.24M +1.1M (+53.2%) | 2.47% +0.865 pp | 0.00% +0.000 pp | USD6.23 -1.8% | 5 qtrs — |
| 4 | BLACKROCK, INC. | 432.0K +150.0K (+53.2%) | 2.64M +757.0K (+40.1%) | 2.02% +0.584 pp | 0.00% +0.000 pp | USD6.26 -2.2% | 5 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 207.7K +62.3K (+42.9%) | 1.27M +298.6K (+30.7%) | 0.97% +0.231 pp | 0.00% +0.000 pp | USD6.39 -4.2% | 6 qtrs — |
| 6 | NORTHERN TRUST CORP | 101.4K +16.0K (+18.7%) | 620.7K +49.0K (+8.6%) | 0.47% +0.039 pp | 0.00% +0.000 pp | USD6.46 -5.3% | 4 qtrs — |
| 7 | TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC | 94.6K +94.6K (+100.0%) | 578.9K +578.9K (+100.0%) | 0.44% +0.442 pp | 0.03% +0.033 pp | USD6.12 +0.0% | 1 qtrs NEW |
| 8 | STATE STREET CORP | 56.3K +6.4K (+12.8%) | 344.5K +10.7K (+3.2%) | 0.26% +0.009 pp | 0.00% +0.000 pp | USD6.30 -2.9% | 3 qtrs — |
| 9 | ROYAL BANK OF CANADA | 35.3K +22.3K (+172.2%) | 215.0K +129.0K (+150.0%) | 0.16% +0.099 pp | 0.00% +0.000 pp | USD6.33 -3.3% | 6 qtrs — |
| 10 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 31.0K +31.0K (+100.0%) | 189.6K +189.6K (+100.0%) | 0.14% +0.145 pp | 0.00% +0.004 pp | USD6.12 +0.0% | 1 qtrs NEW |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 23.8K +9.1K (+61.5%) | 145.9K +47.1K (+47.7%) | 0.11% +0.036 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 12 | ROCK CREEK GROUP, LP | 21.8K +21.8K (+100.0%) | 133.2K +133.2K (+100.0%) | 0.10% +0.102 pp | 0.01% +0.015 pp | USD6.12 +0.0% | 1 qtrs NEW |
| 13 | WELLS FARGO & COMPANY/MN | 20.1K +6.6K (+48.8%) | 123.3K +32.7K (+36.1%) | 0.09% +0.025 pp | 0.00% +0.000 pp | USD6.13 -0.2% | 3 qtrs — |
| 14 | SFMG, LLC | 20.0K +3.0K (+17.6%) | 122.4K +8.7K (+7.6%) | 0.09% +0.007 pp | 0.01% +0.000 pp | USD6.55 -6.6% | 4 qtrs — |
| 15 | GLEASON GROUP, INC. | 19.0K +— (+0.0%) | 116.5K -10.8K (-8.5%) | 0.09% -0.008 pp | 0.01% -0.001 pp | USD6.11 +0.2% | 3 qtrs — |
| 16 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 18.5K -783.0 (-4.1%) | 113.3K -15.8K (-12.2%) | 0.09% -0.012 pp | 0.00% +0.000 pp | USD6.24 -1.9% | 4 qtrs — |
| 17 | JANE STREET GROUP, LLC | 16.6K +16.6K (+100.0%) | 101.7K +101.7K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.000 pp | USD6.12 +0.0% | 1 qtrs NEW |
| 18 | BARCLAYS PLC | 14.9K +6.1K (+68.6%) | 91.5K +32.2K (+54.2%) | 0.07% +0.025 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 19 | MORGAN STANLEY | 13.1K +5.5K (+72.0%) | 80.3K +29.3K (+57.4%) | 0.06% +0.023 pp | 0.00% +0.000 pp | USD6.24 -1.9% | 5 qtrs — |
| 20 | LPL FINANCIAL LLC | 13.0K -3.3K (-20.0%) | 79.3K -29.1K (-26.9%) | 0.06% -0.022 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 21 | BANK OF NEW YORK MELLON CORP | 12.6K +12.6K (+100.0%) | 76.9K +76.9K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD6.12 +0.0% | 1 qtrs NEW |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 10.3K +10.3K (+100.0%) | 62.7K +62.7K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.000 pp | USD6.12 +0.0% | 1 qtrs NEW |
| 23 | RHUMBLINE ADVISERS | 9.5K +766.0 (+8.7%) | 58.3K -310.0 (-0.5%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 24 | DEUTSCHE BANK AG\ | 9.3K +8.1K (+640.0%) | 57.0K +48.6K (+576.9%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD6.12 +0.0% | 3 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 9.1K +4.2K (+86.0%) | 55.5K +22.9K (+70.1%) | 0.04% +0.018 pp | 0.00% +0.000 pp | USD6.12 +0.0% | 6 qtrs — |
| 26 | ABS DIRECT EQUITY FUND LLC | 6.6K +6.6K (+100.0%) | 40.4K +40.4K (+100.0%) | 0.03% +0.031 pp | 0.05% +0.048 pp | USD6.12 +0.0% | 1 qtrs NEW |
| 27 | GLOBAL RETIREMENT PARTNERS, LLC | 6.3K +— (+0.0%) | 38.3K -3.6K (-8.5%) | 0.03% -0.003 pp | 0.00% 0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 28 | NEW YORK STATE COMMON RETIREMENT FUND | 6.2K +— (+0.0%) | 37.9K -3.5K (-8.5%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 29 | UBS GROUP AG | 5.1K -3.8K (-42.6%) | 31.3K -28.4K (-47.5%) | 0.02% -0.022 pp | 0.00% +0.000 pp | USD6.94 -11.8% | 5 qtrs — |
| 30 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 4.4K +1.7K (+64.9%) | 27.1K +9.1K (+50.8%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 31 | JPMORGAN CHASE & CO | 3.8K +1.3K (+52.8%) | 23.2K +6.6K (+39.8%) | 0.02% +0.005 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 5 qtrs — |
| 32 | BNP PARIBAS ARBITRAGE, SNC | 2.4K +832.0 (+53.3%) | 14.6K +4.2K (+40.3%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD6.27 -2.4% | 3 qtrs — |
| 33 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.6K -7.0 (-0.4%) | 10.0K -980.0 (-8.9%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD6.69 -8.5% | 6 qtrs — |
| 34 | LEGAL & GENERAL GROUP PLC | 1.3K +571.0 (+80.6%) | 7.8K +3.1K (+65.3%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 35 | ADVISOR GROUP HOLDINGS, INC. | 1.0K +— (+0.0%) | 6.1K -2.3K (-27.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 36 | AMERITAS INVESTMENT PARTNERS, INC. | 601.00 +— (+0.0%) | 3.7K -343.0 (-8.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 37 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 585.00 +217.0 (+59.0%) | 3.6K +1.1K (+45.4%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 38 | RUSSELL INVESTMENTS GROUP, LTD. | 487.00 +— (+0.0%) | 3.0K -278.0 (-8.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.69 -8.5% | 2 qtrs — |
| 39 | AMALGAMATED BANK | 298.00 +97.0 (+48.3%) | 2.0K +1.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.11 +0.2% | 3 qtrs — |
| 40 | FMR LLC | 280.00 -293.0 (-51.1%) | 1.7K -2.1K (-55.3%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD6.37 -3.9% | 3 qtrs — |
| 41 | CITIGROUP INC | 215.00 -45.0 (-17.3%) | 1.3K -423.0 (-24.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.31 -3.0% | 6 qtrs — |
| 42 | STERLING CAPITAL MANAGEMENT LLC | 40.00 +25.0 (+166.7%) | 245.00 +145.0 (+145.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.10 +0.3% | 3 qtrs — |
| 43 | EVERSOURCE WEALTH ADVISORS, LLC | 2.00 -68.0 (-97.1%) | 12.00 -457.0 (-97.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.50 -5.8% | 2 qtrs — |
| 44 | TRUE WEALTH DESIGN, LLC | 1.00 +1.0 (+100.0%) | 7.00 +7.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.00 +2.0% | 1 qtrs NEW |
| 45 | PROSIGHT MANAGEMENT, LP | — -885.0 (-100.0%) | — -5.9K (-100.0%) | 0.00% -0.005 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 46 | FREESTONE CAPITAL HOLDINGS, LLC | — -10.0K (-100.0%) | — -66.9K (-100.0%) | 0.00% -0.051 pp | 0.00% -0.002 pp | USD— | 5 qtrs SOLD |
| 47 | WEALTHSPIRE ADVISORS, LLC | — -5.0K (-100.0%) | — -33.5K (-100.0%) | 0.00% -0.025 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 48 | PNC FINANCIAL SERVICES GROUP, INC. | — -384.0 (-100.0%) | — -2.6K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 49 | SRS CAPITAL ADVISORS, INC. | — -60.0 (-100.0%) | — -401.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 50 | NORTHWESTERN UNIVERSITY | — -6.5K (-100.0%) | — -43.4K (-100.0%) | 0.00% -0.033 pp | 0.00% -0.077 pp | USD— | 6 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.00% | 46.3K | 0.60% |
| 2 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 17.8K | 0.06% |
| 3 | Vanguard Russell 2000 ETF VTWO | 0.00% | 95.4K | 0.06% |
| 4 | Vanguard Extended Market ETF VXF | 0.00% | 209.4K | 0.05% |
| 5 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.4K | 0.17% |
| 6 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.2K | 0.03% |
| 7 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 249.55 | 0.17% |
| 8 | Vanguard Total Stock Market ETF VTI | 0.00% | 577.3K | 0.03% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.3K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 688.60 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
447.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+447,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Huber Martin H. Jr. | Director | — | — | Non-Qualified Stock Options | 30,000 | 3.00 | 90.0K | 0 | D | ↗ |
| 2026-04-01 | SCHMITT DANIEL M | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 237,000 | 2.49 | 590.1K | 237,000 | D | ↗ |
| 2026-04-01 | Mazar Andrew Paul | Officer | A-Award | A | Employee Stock Option (right to buy) | 105,000 | 2.49 | 261.5K | 105,000 | D | ↗ |
| 2026-04-01 | LYTLE PAUL J | Officer | A-Award | A | Employee Stock Option (right to buy) | 105,000 | 2.49 | 261.5K | 105,000 | D | ↗ |
| 2026-02-13 | SCHMITT DANIEL M | Director / Officer | M-Exempt | D | Restricted Stock Units | 272,055 | 0.00 | — | 272,056 | D | ↗ |
| 2026-01-05 | THOMSON TODD S | Director / 10% Owner | S-Sale | D | Common Stock | 280,000 | 5.80 | 1.62M | 904,795 | I | ↗ |
| 2025-06-27 | Kreis Leslie W. | Director / 10% Owner | P-Purchase | A | Common Stock | 71,428 | 7.00 | 500.0K | 196,428 | I | ↗ |
| 2025-06-27 | Fletcher Aaron G.L. | Director / 10% Owner | P-Purchase | A | Warrant (Right to Buy) | 71,428 | 7.00 | 500.0K | 71,428 | I | ↗ |
| 2025-06-27 | Bios Equity COF, LP | Director / 10% Owner | P-Purchase | A | Warrant (Right to Buy) | 71,428 | 7.00 | 500.0K | 71,428 | I | ↗ |
| 2025-05-22 | Zabrowski Dan | Director | A-Award | A | Stock Options | 15,000 | 10.10 | 151.5K | 15,000 | D | ↗ |
| 2025-05-22 | THOMSON TODD S | Director / 10% Owner | A-Award | A | Stock Options | 15,000 | 10.10 | 151.5K | 15,000 | D | ↗ |
| 2025-05-22 | Sawhney Roger | Director | A-Award | A | Stock Options | 15,000 | 10.10 | 151.5K | 15,000 | D | ↗ |
| 2025-05-22 | RONNEBERG AMY L | Director | A-Award | A | Stock Options | 15,000 | 10.10 | 151.5K | 15,000 | D | ↗ |
| 2025-05-22 | Keyes Jason A | Director | A-Award | A | Stock Options | 15,000 | 10.10 | 151.5K | 15,000 | D | ↗ |
| 2025-05-22 | Fletcher Aaron G.L. | Director / 10% Owner | A-Award | A | Stock Options | 15,000 | 10.10 | 151.5K | 15,000 | D | ↗ |
| 2025-04-01 | SCHMITT DANIEL M | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 204,285 | 6.70 | 1.37M | 204,285 | D | ↗ |
| 2025-04-01 | Mazar Andrew Paul | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,346 | 6.70 | 739.3K | 110,346 | D | ↗ |
| 2025-04-01 | LYTLE PAUL J | Officer | A-Award | A | Employee Stock Option (right to buy) | 49,394 | 6.70 | 330.9K | 49,394 | D | ↗ |
| 2014-05-21 | PATTERSON ARTHUR C | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 1,041,970 | — | ↗ |
| 2013-05-22 | PATTERSON ARTHUR C | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 1,025,970 | — | ↗ |
| 2012-12-12 | PATTERSON ARTHUR C | Director | M-Exempt | D | Option (right to buy) | 16,000 | 4.20 | 67.2K | 97,000 | — | ↗ |
| 2012-05-24 | PATTERSON ARTHUR C | Director | M-Exempt | A | Common Stock | 10,000 | 5.56 | 55.6K | 783,970 | — | ↗ |
| 2012-05-23 | PATTERSON ARTHUR C | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 773,970 | — | ↗ |
| 2011-10-12 | PATTERSON ARTHUR C | Director | M-Exempt | A | Common Stock | 15,000 | 3.75 | 56.3K | 765,970 | — | ↗ |
| 2011-05-25 | PATTERSON ARTHUR C | Director | A-Award | A | Option (right to buy) | 16,000 | 5.47 | 87.5K | 302,000 | — | ↗ |
| 2010-05-26 | PATTERSON ARTHUR C | Director | A-Award | A | Option (right to buy) | 16,000 | 4.20 | 67.2K | 316,000 | — | ↗ |
| 2009-08-27 | BEITZEL GEORGE B | Director | M-Exempt | D | Option (right to buy) | 10,000 | 1.99 | 19.9K | 290,000 | — | ↗ |
| 2009-08-26 | BEITZEL GEORGE B | Director | M-Exempt | D | Option (right to buy) | 40,000 | 1.49 | 59.6K | 300,000 | — | ↗ |
| 2009-05-21 | PATTERSON ARTHUR C | Director | A-Award | A | Option (right to buy) | 25,000 | 4.60 | 115.0K | 310,000 | — | ↗ |
| 2009-05-21 | BEITZEL GEORGE B | Director | A-Award | A | Option (right to buy) | 25,000 | 4.60 | 115.0K | 340,000 | — | ↗ |
| 2009-05-20 | PATTERSON ARTHUR C | Director | M-Exempt | A | Common Stock | 10,000 | 4.75 | 47.5K | 744,970 | — | ↗ |
| 2008-05-21 | PATTERSON ARTHUR C | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.65 | 116.3K | 25,000 | — | ↗ |
| 2008-05-21 | BEITZEL GEORGE B | Director | A-Award | A | Option (right to buy) | 25,000 | 4.65 | 116.3K | 25,000 | — | ↗ |
| 2007-08-31 | BEITZEL GEORGE B | Director | M-Exempt | D | Option (right to buy) | 50,000 | 1.49 | 74.5K | 265,000 | — | ↗ |
| 2007-08-30 | BEITZEL GEORGE B | Director | M-Exempt | D | Option (right to buy) | 50,000 | 1.49 | 74.5K | 315,000 | — | ↗ |
| 2007-05-30 | PATTERSON ARTHUR C | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 6.20 | 155.0K | 25,000 | — | ↗ |
| 2007-05-30 | BEITZEL GEORGE B | Director | A-Award | A | Option (right to buy) | 25,000 | 6.20 | 155.0K | 25,000 | — | ↗ |
| 2006-05-30 | PATTERSON ARTHUR C | Director | J-Other | A | Stock Option (right to buy) | 30,000 | 4.03 | 120.9K | 30,000 | — | ↗ |
| 2006-05-30 | BEITZEL GEORGE B | Director | A-Award | A | Option (right to buy) | 30,000 | 4.03 | 120.9K | 30,000 | — | ↗ |
| 2006-05-24 | PATTERSON ARTHUR C | Director | J-Other | A | Stock Option (right to buy) | 10,000 | 3.77 | 37.7K | 1 | — | ↗ |
| 2006-05-24 | BEITZEL GEORGE B | Director | A-Award | A | Option (right to buy) | 10,000 | 3.77 | 37.7K | 1 | — | ↗ |
| 2005-05-25 | PATTERSON ARTHUR C | Director | J-Other | D | Stock Option (right to buy) | 10,000 | 1.99 | 19.9K | 163,750 | — | ↗ |
| 2005-05-25 | BEITZEL GEORGE B | Director | A-Award | A | Option (right to buy) | 10,000 | 1.99 | 19.9K | 1 | — | ↗ |
| 2004-11-24 | BEITZEL GEORGE B | Director | S-Sale | D | Common Stock | 15,000 | 2.41 | 36.2K | 0 | — | ↗ |
| 2004-05-26 | PATTERSON ARTHUR C | Director | J-Other | A | Stock Option (right to buy) | 10,000 | 3.65 | 36.5K | 111,250 | — | ↗ |
| 2004-05-26 | BEITZEL GEORGE B | Director | A-Award | A | Option (right to buy) | 10,000 | 3.65 | 36.5K | 10,000 | — | ↗ |
| 2004-05-14 | PATTERSON ARTHUR C | Director | P-Purchase | A | Common Stock | 10,000 | 3.09 | 30.9K | 734,971 | — | ↗ |
| 2004-05-12 | PATTERSON ARTHUR C | Director | P-Purchase | A | Common Stock | 20,000 | 3.09 | 61.7K | 734,971 | — | ↗ |
| 2004-05-10 | PATTERSON ARTHUR C | Director | P-Purchase | A | Common Stock | 5,000 | 3.12 | 15.6K | 704,971 | — | ↗ |
| 2004-05-07 | PATTERSON ARTHUR C | Director | P-Purchase | A | Common Stock | 5,450 | 3.18 | 17.3K | 664,664 | — | ↗ |
| 2004-05-06 | PATTERSON ARTHUR C | Director | P-Purchase | A | Common Stock | 7,050 | 3.20 | 22.6K | 664,664 | — | ↗ |
| 2004-05-05 | PATTERSON ARTHUR C | Director | P-Purchase | A | Common Stock | 5,000 | 3.20 | 16.0K | 664,664 | — | ↗ |
Executive team
Top executives
Shares Outstanding
23.93M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Daniel M. Schmitt President and Chief Executive Officer | 570.0K | 142.3K | — | 1.45M | — | — | 2.17M | 67.12% | ↗ |
| 2 | 2025 | Andrew P. Mazar, Ph. D. Chief Operating Officer | 450.0K | 102.2K | — | 867.4K | — | — | 1.42M | 61.10% | ↗ |
| 3 | 2025 | Paul Lytle Chief Financial Officer | 435.4K | 79.1K | — | 491.9K | — | — | 1.01M | 48.88% | ↗ |
| 4 | 2024 | Daniel M. Schmitt President and Chief Executive Officer | 400.0K | 200.0K | 4.98M | — | — | — | 5.58M | 89.24% | ↗ |
| 5 | 2024 | Paul Lytle Chief Financial Officer | 210.0K | 84.0K | — | 1.50M | — | 98.5K | 1.90M | 79.30% | ↗ |
| 6 | 2024 | Andrew P. Mazar, Ph. D. Chief Operating Officer | 450.0K | 225.0K | — | — | — | — | 675.0K | 0.00% | ↗ |
| 7 | 2023 | Andrew P. Mazar, Ph. D. Chief Operating Officer | 450.0K | 157.5K | — | 58.6K | — | — | 666.1K | 8.80% | ↗ |
| 8 | 2023 | Daniel M. Schmitt President and Chief Executive Officer | 400.0K | 120.0K | — | — | — | — | 520.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Schmitt | Chief Executive Officer, President & Director | 712.3K | male |
| Andrew Mazar | Co-Founder & Chief Operating Officer | 552.2K | — |
| Paul J. Lytle | Chief Financial Officer | 514.4K | male |
| Alan Kozikowski | Scientific Founder and Advisor | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACTU
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
